GBA1 Parkinson's Disease Research Catalyst Program
The Michael J. Fox Foundation for Parkinson's Research
About this archived opportunity
The GBA1-PD Research Catalyst Program seeks to build a deeper, globally integrated understanding of GBA1-associated Parkinson’s disease by aligning efforts across geographies and maximizing the value of shared datasets and research assets. Funding will support hypothesis-driven projects with an emphasis on integrative, cross-cohort analyses and the systematic characterization and standardization of models to enable broad use by the research community. The GBA1-PD Research Catalyst Program seeks to build a deeper, globally integrated understanding of GBA1-associated Parkinson’s disease by aligning efforts across geographies and maximizing the value of shared datasets and research assets. Funding will support hypothesis-driven projects with an emphasis on integrative, cross-cohort analyses and the systematic characterization and standardization of models to enable broad use by the resea...
Historical details
- Status
- Closed
- Deadline
- July 22, 2026
- First captured
- June 10, 2026
- Award
- $300,000
- Publisher reference
- https://www.michaeljfox.org/grant/gba1-parkinsons-disease-research-catalyst-program
Eligibility: Academic
This opportunity has closed
GBA1 Parkinson's Disease Research Catalyst Program
by The Michael J. Fox Foundation for Parkinson's Research
Get notified when similar opportunities open
We'll save this search and email you when new parkinson, disease, research opportunities are posted. Free.
Related opportunities
- Parkinson's Disease Therapeutics Pipeline ProgramThe Michael J. Fox Foundation for Parkinson's Research
- Catalyze: Product Definition for Small Molecules, Biologics and Combination Products - Target Identification and Validation, and Preliminary Product/Lead Series Identification (R61/R33 Clinical Trials Not Allowed)National Institutes of HealthCloses Dec 2027
- Catalyze: Product Definition Medical Device Prototype Optimization (R33 - Clinical Trial Not Allowed)National Institutes of HealthCloses Dec 2027
- Catalyze: Product Definition for Small Molecules, Biologics, and Combination Products - Preliminary Product/Lead Series Identification and Combination Product Prototype (R33 - Clinical Trial Not Allowed)National Institutes of HealthCloses Dec 2027
- Simons Foundation: Conference Support for Rare Neurodevelopmental Disorder Communities Participating in Simons SearchlightSimons FoundationUp to $15K